Sales & Marketing News | pharmaphorum

News

Samsung seeks 'interchangeable' label for Humira biosimilar

While there are already a number of biosimilars of AbbVie's big-selling Humira on the US market, so far, only one – Boehringer Ingelheim's

News

AZ and BMS resolve checkpoint inhibitor patent disputes

AstraZeneca has said that a trio of lawsuits filed by Bristol-Myers Squibb and Ono Pharma alleging patent infringement with its checkpoint inhibitor drugs Imjudo and Imfin

News

Jemperli cleared for frontline use in endometrial cancer

GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherap

News

Apellis slides on side effect reports with new eye drug

Apellis' share price came under pressure today after it revealed new details about a rare but serious side effect with its recently-approved Syfovre therapy for eye diseas

News

Purdue bankruptcy case elevated to SCOTUS

The US Government has asked the Supreme Court to block Purdue Pharma from completing a bankruptcy settlement that would shield its Sackler family owners from lawsuits.

News

After cutbacks, Biogen adds new drug with $7.3bn Reata buy

Biogen has turned to M&A to offset its recent troubles with pipeline failures and aborted product launches, agreeing to a $7.3 billion deal to acquire Reata Pharma.

Samsung seeks 'interchangeable' label for Humira biosimilar

AZ and BMS resolve checkpoint inhibitor patent disputes

Jemperli cleared for frontline use in endometrial cancer

Apellis slides on side effect reports with new eye drug

Purdue bankruptcy case elevated to SCOTUS

After cutbacks, Biogen adds new drug with $7.3bn Reata buy

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks